Monogram Technologies (NASDAQ: MGRM) is a medical device company developing a product solution architecture to enable patient-optimized orthopedic implants at scale by linking 3D printing and robotics with advanced pre-operative imaging. The company delivered its first surgical robot in November 2023 and submitted its 510(k) on July 19th and the application passed the Administrative Review. The first live in patient surgery OUS is expected in early 2025. The company has an estimated $16.0-$17.0 million in cash after the recent equity offering. We believe MGRM stock to be undervalued at this time with several significant potential catalysts within the next 12 months.
